Compare · DXCM vs MOTS
DXCM vs MOTS
Side-by-side comparison of DexCom Inc. (DXCM) and Motus GI Holdings Inc. (MOTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MOTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 1706.9x MOTS ($16.2M).
- DXCM has hit the wire 6 times in the past 4 weeks while MOTS has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 1 for MOTS).
- Company
- DexCom Inc.
- Motus GI Holdings Inc.
- Price
- $71.54+1.52%
- $0.18-30.42%
- Market cap
- $27.61B
- $16.2M
- 1M return
- +2.57%
- -
- 1Y return
- -20.08%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2018
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Motus GI Holdings Inc.
Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with colonoscopy in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest MOTS
- Amendment: SEC Form SC 13G/A filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form 15-12G filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.